165 related articles for article (PubMed ID: 15689157)
21. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design.
Schulze-Gahmen U; De Bondt HL; Kim SH
J Med Chem; 1996 Nov; 39(23):4540-6. PubMed ID: 8917641
[TBL] [Abstract][Full Text] [Related]
22. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol.
de Azevedo WF; Canduri F; da Silveira NJ
Biochem Biophys Res Commun; 2002 Apr; 293(1):566-71. PubMed ID: 12054639
[TBL] [Abstract][Full Text] [Related]
23. Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6.
Noh SJ; Li Y; Xiong Y; Guan KL
Cancer Res; 1999 Feb; 59(3):558-64. PubMed ID: 9973200
[TBL] [Abstract][Full Text] [Related]
24. Characterization of murine gammaherpesvirus 68 v-cyclin interactions with cellular cdks.
Upton JW; van Dyk LF; Speck SH
Virology; 2005 Oct; 341(2):271-83. PubMed ID: 16102793
[TBL] [Abstract][Full Text] [Related]
25. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine.
Schulze-Gahmen U; Brandsen J; Jones HD; Morgan DO; Meijer L; Vesely J; Kim SH
Proteins; 1995 Aug; 22(4):378-91. PubMed ID: 7479711
[TBL] [Abstract][Full Text] [Related]
26. Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex.
Ellis M; Chew YP; Fallis L; Freddersdorf S; Boshoff C; Weiss RA; Lu X; Mittnacht S
EMBO J; 1999 Feb; 18(3):644-53. PubMed ID: 9927424
[TBL] [Abstract][Full Text] [Related]
27. Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma.
Easton J; Wei T; Lahti JM; Kidd VJ
Cancer Res; 1998 Jun; 58(12):2624-32. PubMed ID: 9635589
[TBL] [Abstract][Full Text] [Related]
28. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins.
Swanton C; Mann DJ; Fleckenstein B; Neipel F; Peters G; Jones N
Nature; 1997 Nov; 390(6656):184-7. PubMed ID: 9367157
[TBL] [Abstract][Full Text] [Related]
29. ATP-site directed inhibitors of cyclin-dependent kinases.
Gray N; Détivaud L; Doerig C; Meijer L
Curr Med Chem; 1999 Sep; 6(9):859-75. PubMed ID: 10495356
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex.
Jeffrey PD; Russo AA; Polyak K; Gibbs E; Hurwitz J; Massagué J; Pavletich NP
Nature; 1995 Jul; 376(6538):313-20. PubMed ID: 7630397
[TBL] [Abstract][Full Text] [Related]
31. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues.
Honma T; Yoshizumi T; Hashimoto N; Hayashi K; Kawanishi N; Fukasawa K; Takaki T; Ikeura C; Ikuta M; Suzuki-Takahashi I; Hayama T; Nishimura S; Morishima H
J Med Chem; 2001 Dec; 44(26):4628-40. PubMed ID: 11741480
[TBL] [Abstract][Full Text] [Related]
32. Solution structure of p21(Waf1/Cip1/Sdi1) C-terminal domain bound to Cdk4.
Sung YH; Shin J; Shin J; Lee W
J Biomol Struct Dyn; 2001 Dec; 19(3):419-27. PubMed ID: 11790141
[TBL] [Abstract][Full Text] [Related]
33. Structure-guided discovery of cyclin-dependent kinase inhibitors.
Fischmann TO; Hruza A; Duca JS; Ramanathan L; Mayhood T; Windsor WT; Le HV; Guzi TJ; Dwyer MP; Paruch K; Doll RJ; Lees E; Parry D; Seghezzi W; Madison V
Biopolymers; 2008 May; 89(5):372-9. PubMed ID: 17937404
[TBL] [Abstract][Full Text] [Related]
34. Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells.
Ahmad N; Adhami VM; Afaq F; Feyes DK; Mukhtar H
Clin Cancer Res; 2001 May; 7(5):1466-73. PubMed ID: 11350919
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical analysis of the D-type cyclin-dependent kinases Cdk4 and Cdk6, using a series of monoclonal antibodies.
Lukas C; Jensen SK; Bartkova J; Lukas J; Bartek J
Hybridoma; 1999 Jun; 18(3):225-34. PubMed ID: 10475236
[TBL] [Abstract][Full Text] [Related]
36. Low levels of cyclin D and nonfunctional Rb protein affect cdk6 association with cyclin-dependent kinase inhibitor p27(Kip1).
Kwon TK; Park JW
Biochem Biophys Res Commun; 2001 Jun; 284(1):106-11. PubMed ID: 11374878
[TBL] [Abstract][Full Text] [Related]
37. Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16.
Dixon-Clarke SE; Shehata SN; Krojer T; Sharpe TD; von Delft F; Sakamoto K; Bullock AN
Biochem J; 2017 Feb; 474(5):699-713. PubMed ID: 28057719
[TBL] [Abstract][Full Text] [Related]
38. Transforming activity of Fbxo7 is mediated specifically through regulation of cyclin D/cdk6.
Laman H; Funes JM; Ye H; Henderson S; Galinanes-Garcia L; Hara E; Knowles P; McDonald N; Boshoff C
EMBO J; 2005 Sep; 24(17):3104-16. PubMed ID: 16096642
[TBL] [Abstract][Full Text] [Related]
39. Selectivity and potency of cyclin-dependent kinase inhibitors.
Sridhar J; Akula N; Pattabiraman N
AAPS J; 2006 Mar; 8(1):E204-21. PubMed ID: 16584130
[TBL] [Abstract][Full Text] [Related]
40. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
Bettayeb K; Tirado OM; Marionneau-Lambot S; Ferandin Y; Lozach O; Morris JC; Mateo-Lozano S; Drueckes P; Schächtele C; Kubbutat MH; Liger F; Marquet B; Joseph B; Echalier A; Endicott JA; Notario V; Meijer L
Cancer Res; 2007 Sep; 67(17):8325-34. PubMed ID: 17804748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
